• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨Paget病患者循环I型前胶原前肽的评估。

Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.

作者信息

Bonnin M R, Moragues C, Nolla J M, Lirón F J, Roig-Escofet D, Navarro M A

机构信息

Hormone Unit, Ciudad Sanitaria y Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

出版信息

Clin Chem Lab Med. 1998 Jan;36(1):53-5. doi: 10.1515/CCLM.1998.010.

DOI:10.1515/CCLM.1998.010
PMID:9594087
Abstract

We evaluated circulating aminoterminal and carboxyterminal propeptides of type I procollagen and total alkaline phosphatase levels in eighty consecutive patients affected by Paget's disease of bone. We compared the biochemical data with the extent of bone disease calculated on the basis of the bone scintigraphic indices. Serum aminoterminal propeptide of type I procollagen levels were high in 77% of patients, serum carboxyterminal propeptide of type I procollagen levels in 22% and serum total alkaline phosphatase levels in 76%. We found significant correlations between the three markers studied. The three biochemical markers correlated significantly with the bone scintigraphic activity indices, but the highest correlation coefficient was between the aminoterminal propeptide and total alkaline phosphatase. We conclude that there is a discrepancy between serum levels of the propeptides studied in relation to Paget's disease of bone. The sensitivity of the carboxyterminal propeptide of type I procollagen in this disease is low. In contrast the aminoterminal propeptide may be as sensitive a marker for the evaluation of this disorder as total alkaline phosphatase, and in addition may be more specific.

摘要

我们评估了80例连续性骨Paget病患者的血清I型前胶原氨基端和羧基端前肽以及总碱性磷酸酶水平。我们将这些生化数据与基于骨闪烁显像指数计算的骨病范围进行了比较。77%的患者血清I型前胶原氨基端前肽水平升高,22%的患者血清I型前胶原羧基端前肽水平升高,76%的患者血清总碱性磷酸酶水平升高。我们发现所研究的三种标志物之间存在显著相关性。这三种生化标志物与骨闪烁显像活性指数显著相关,但氨基端前肽与总碱性磷酸酶之间的相关系数最高。我们得出结论,在所研究的与骨Paget病相关的前肽血清水平之间存在差异。I型前胶原羧基端前肽在该疾病中的敏感性较低。相比之下,氨基端前肽作为评估这种疾病的标志物可能与总碱性磷酸酶一样敏感,此外可能更具特异性。

相似文献

1
Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.骨Paget病患者循环I型前胶原前肽的评估。
Clin Chem Lab Med. 1998 Jan;36(1):53-5. doi: 10.1515/CCLM.1998.010.
2
Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.在评估佩吉特病活动度时骨转换生化标志物与骨闪烁显像指标之间的关系。
Arthritis Rheum. 1997 Mar;40(3):461-8. doi: 10.1002/art.1780400312.
3
Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.骨闪烁显像在评估佩吉特病活动度中的定量评估
Nucl Med Commun. 1999 Jun;20(6):525-8. doi: 10.1097/00006231-199906000-00006.
4
Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.骨转换生化标志物在评估佩吉特病治疗反应中的应用价值。
Bone. 2001 Nov;29(5):447-52. doi: 10.1016/s8756-3282(01)00592-0.
5
Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.骨转换生化标志物在评估佩吉特病活动度中的鉴别价值。
J Bone Miner Res. 1995 Mar;10(3):458-65. doi: 10.1002/jbmr.5650100318.
6
Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.用替鲁膦酸盐治疗对通过骨标志物和骨闪烁显像评估的佩吉特病活动的影响与利塞膦酸盐相似。
Clin Exp Rheumatol. 2007 Mar-Apr;25(2):206-10.
7
Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.骨Paget病双膦酸盐治疗后的长期生化反应。建议的治疗监测间隔时间。
Rheumatology (Oxford). 2004 Jul;43(7):869-74. doi: 10.1093/rheumatology/keh185. Epub 2004 Mar 30.
8
Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.骨重塑生化标志物在接受替鲁膦酸盐治疗的佩吉特骨病患者管理中的疗效差异。
Calcif Tissue Int. 1996 Aug;59(2):95-9. doi: 10.1007/s002239900093.
9
Circulating and tissue-derived isoforms of bone alkaline phosphatase in Paget's disease of bone.成骨不全症中循环和组织来源的骨碱性磷酸酶同工型。
Scand J Clin Lab Invest. 2010 Apr;70(2):128-35. doi: 10.3109/00365511003642527.
10
Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.患有颅骨受累的佩吉特病患者对双膦酸盐治疗的生化反应。
Calcif Tissue Int. 2006 Jul;79(1):22-6. doi: 10.1007/s00223-005-0247-9. Epub 2006 Jul 24.

引用本文的文献

1
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.CTX-I 和 PINP 作为骨转换标志物的应用:国家骨健康联盟建议规范样本处理和患者准备,以减少分析前的变异性。
Osteoporos Int. 2017 Sep;28(9):2541-2556. doi: 10.1007/s00198-017-4082-4. Epub 2017 Jun 19.
2
Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.骨Paget病中的骨转换标志物:一项系统评价和荟萃分析。
Osteoporos Int. 2015 Jul;26(7):1875-91. doi: 10.1007/s00198-015-3095-0. Epub 2015 Jun 3.